Luigi Bergamaschini

Dirigente medico

Richiedi appuntamento

Specializzazione

Geriatria
Medicina interna

Istituto

IRCCS Milano
Via Camaldoli, 64
20138 Milano (MI)

Contatti

02.50725220
[javascript protected email address]

Richiedi appuntamento

Inappropriate prescribing in intermediate care facilities. Bonini G, Pasina L, Cortesi L, Cesari M, Bergamaschini L.Aging Clin Exp Res. 2021 Apr;33(4):1085-1088.
Predictors of Successful Oxygen Weaning in Older Patients Undergoing Pulmonary Rehabilitation. Nestola T, Orlandini L, Ferrari A, Monzani V, Gallimbeni G, Bergamaschini LC, Cesari M.J Am Med Dir Assoc. 2020 Aug;21(8):1153-1156.
Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study. Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P, Deliliers GL.Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e461-e467.
Use of the Frailty Index in Older Persons With Chronic Kidney Disease. Vezza C, Vettoretti S, Caldiroli L, Bergamaschini L, Messa P, Cesari M.J Am Med Dir Assoc. 2019 Sep;20(9):1179-1180.
Current and emerging biologics for the treatment of hereditary angioedema. Perego F, Wu MA, Valerieva A, Caccia S, Suffritti C, Zanichelli A, Bergamaschini L, Cicardi M.Expert Opin Biol Ther. 2019 Jun;19(6):517-526.
Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L.J Thromb Thrombolysis. 2019 Jan;47(1):155-156.
High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L.J Thromb Thrombolysis. 2018 Jan;45(1):106-113.
Personalized treatment strategies for elderly patients with myelodysplastic syndromes. Castelli R, Bergamaschini L, Schiavon R, Lambertenghi-Deliliers G.Expert Rev Hematol. 2017 Dec;10(12):1077-1086.
Transcriptional and epigenetic phenomena in peripheral blood cells of monozygotic twins discordant for alzheimer's disease, a case report. D'Addario C, Candia SB, Arosio B, Di Bartolomeo M, Abbate C, Casè A, Candeletti S, Romualdi P, Damanti S, Maccarrone M, Bergamaschini L, Mari D.J Neurol Sci. 2017 Jan 15;372:211-216.
Alzheimer's disease: another target for heparin therapy. Bergamaschini L, Rossi E, Vergani C, De Simoni MG.ScientificWorldJournal. 2009 Sep 1;9:891-908.
Inappropriate prescribing in intermediate care facilities. Bonini G, Pasina L, Cortesi L, Cesari M, Bergamaschini L.Aging Clin Exp Res. 2021 Apr;33(4):1085-1088.
Predictors of Successful Oxygen Weaning in Older Patients Undergoing Pulmonary Rehabilitation. Nestola T, Orlandini L, Ferrari A, Monzani V, Gallimbeni G, Bergamaschini LC, Cesari M.J Am Med Dir Assoc. 2020 Aug;21(8):1153-1156.
Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study. Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P, Deliliers GL.Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e461-e467.
Use of the Frailty Index in Older Persons With Chronic Kidney Disease. Vezza C, Vettoretti S, Caldiroli L, Bergamaschini L, Messa P, Cesari M.J Am Med Dir Assoc. 2019 Sep;20(9):1179-1180.
Current and emerging biologics for the treatment of hereditary angioedema. Perego F, Wu MA, Valerieva A, Caccia S, Suffritti C, Zanichelli A, Bergamaschini L, Cicardi M.Expert Opin Biol Ther. 2019 Jun;19(6):517-526.
Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L.J Thromb Thrombolysis. 2019 Jan;47(1):155-156.
High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L.J Thromb Thrombolysis. 2018 Jan;45(1):106-113.
Personalized treatment strategies for elderly patients with myelodysplastic syndromes. Castelli R, Bergamaschini L, Schiavon R, Lambertenghi-Deliliers G.Expert Rev Hematol. 2017 Dec;10(12):1077-1086.
Transcriptional and epigenetic phenomena in peripheral blood cells of monozygotic twins discordant for alzheimer's disease, a case report. D'Addario C, Candia SB, Arosio B, Di Bartolomeo M, Abbate C, Casè A, Candeletti S, Romualdi P, Damanti S, Maccarrone M, Bergamaschini L, Mari D.J Neurol Sci. 2017 Jan 15;372:211-216.
Alzheimer's disease: another target for heparin therapy. Bergamaschini L, Rossi E, Vergani C, De Simoni MG.ScientificWorldJournal. 2009 Sep 1;9:891-908.

Accesso rapido

Luigi Bergamaschini

Dirigente medico

Servizi clinici

Curriculum vitae

Pubblicazioni scientifiche

Presta servizio in queste sedi

IRCCS Milano

Profili simili

Laura Bagnara

Laura Calcaterra

Silvia Cacco

Silvia Ferrari

Stefano Negri

Valeria De Grazia

Mappa del sito

Per i pazienti e le loro famiglie

Per i medici

Per i ricercatori

Dove siamo

Chi siamo

Amministrazione trasparente

Bandi e avvisi

Lavora con noi

Luigi Bergamaschini Dirigente medico

Servizi clinici

Curriculum vitae

Pubblicazioni scientifiche

Presta servizio in queste sedi

IRCCS Milano

Profili simili

Laura Bagnara

Laura Calcaterra

Silvia Cacco

Silvia Ferrari

Stefano Negri

Valeria De Grazia

Mappa del sito

Luigi Bergamaschini

Dirigente medico